Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises American Axle & Manufacturing, Inc. (AAM), Detroit
Mandate

Vinge advises American Axle & Manufacturing, Inc. (AAM), Detroit

September 27, 2010

Vinge has advised AAM in connection with the formation of a joint venture with Saab Automobile AB regarding the development of an electric all-wheel-drive and hybrid driveline system for passenger cars and crossover vehicles.

The new company will commence operations in Trollhättan on 1 October 2010. The joint venture company is majority controlled by AAM, which holds two-thirds, with Saab Automobile AB holding the remaining third.

Vinge’s team primarily consisted of partners Fredrik Tengström, Susann Vahlenbreder Hecht, Björn Nicolai and Raoul Svensson together with associates Anna Palmérus, Shoan Panahi, Anna Grandin and Josefin Eriksson.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024